.png "Pharma PLI Scheme Reopens to Boost Bulk Drugs in India Drive")
India has reopened the Pharma PLI scheme for select bulk drugs, giving manufacturers another chance to secure incentives and scale up domestic API production.
.jpeg "Emcure Partners with Roche to Boost Kidney Care Access in India")
Emcure partners with Roche to improve access to life-saving nephrology and transplant treatments in India. The collaboration expands care for CKD, anemia, and organ transplants.
The FDA has approved Ascendis Pharma’s Yuviwel, a once-weekly treatment for children with achondroplasia. The new therapy offers an alternative to daily injections and showed strong growth results in clinical trials.
MGM Healthcare has launched Swayam, Chennai's first comprehensive multidisciplinary geriatric programme. This structured continuity-of-care model integrates outpatient, inpatient, and home-based services to restore and sustain quality of life...
The World Health Organization has unveiled critical updates to the influenza vaccine for the 2026-2027 northern hemisphere season, fully refreshing all strains to counter the rapid spread of the new A(H3N2) subclade K variant and...
Eli Lilly's tirzepatide holds premium pricing in India ahead of March 2026 generics rush. With explosive sales and stronger efficacy than competitors, the company sees room for both branded and low-cost options.
Zydus Lifesciences has received final USFDA approval for its Ivermectin Tablets 3 mg and Dapsone Tablets 25 mg and 100 mg, further expanding its global pharmaceutical footprint.
Eli Lilly and Company reported that its investigational oral GLP-1 receptor agonist, orforglipron, achieved superior blood sugar control and weight loss compared with oral semaglutide in a head-to-head phase 3 trial in adults with type 2 diabet...
CDSCO now allows companies to begin lab testing of new drugs immediately after filing applications. The move aims to speed approvals for manufacturing or importing drugs while keeping technical scrutiny for later stages.
Sanofi Consumer Healthcare India has posted impressive financial results for Q4’25, with a 50% jump in profit after tax (PAT) and a 47% rise in revenue. For the full year, the company achieved a 21% growth in revenue, delivering strong performance ac
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")